Gonorrhea Resistance to Fluoroquinolone Antibiotics
Having a sexually transmitted infection may sound like a terrible thing (and it could be if not treated), but with the suitable medicine, it could easily be put under control.
Gonorrhea is the most common sexually transmitted disease.
It is caused by a bacterium known as Neisseria gonorrhea; this STD has mainly developed resistance to defeat the class of antibiotics used to treat it.
The new resistant strains are a result of inter-species recombination of genes between the principal causative bacterial agent, N. gonorrhea and other commensal strains of the same genus.
This alarming recombination proceeds to stress the diminishing treatment options, and the World Health Organization is concerned that in the near future, there would be a superbug that causes untreatable gonorrhea.
The bug infects the cervix, uterus, and oviducts in women and urethra in both men and women. It can also cause infection in the mouth, throat, eyes, and rectum.
The fact that there is no vaccine to prevent this STD makes humanity rely on antibiotics as the only way of controlling gonorrhea.
During the period between 2000 and 2010, in Kisumu, Kenya, there was a 50% increase in resistance of gonorrhea to ciprofloxacin.
Ciprofloxacin is part of a class of antibiotics known as fluoroquinolones. In 2009, it was reported that people in western Kenya were resistant to fluoroquinolone.
Committed use of the medication will treat the infection, but it will not repair any permanent damage made by the disease.
However, there are fluoroquinolone side effects that patients should be aware of. These antibiotics can include ligament injuries, retinal detachment, aortic dissection, and aortic aneurysm, as well as peripheral neuropathy and tendon injuries.
It is believed that the side effects happen because of the negative impact of fluoroquinolones on hydration.
If you were using fluoroquinolone antibiotics and experienced any side effects, contact hurt.com.
Can a Damaged Road Lead to a Car Accident?
Nephrologists Are Reluctant to Accept Janssen’s INVOKANA